{"title":"810 nm二极管激光系统对季节性变应性鼻炎的疗效观察。","authors":"Katsumi Sasaki, Takafumi Ohshiro, Reiko Sakio, Masahiro Toriumi, Asako Hatano, Emi Fukazawa, Takeyuki Kono, Keisuke Yoshihama, Kaoru Ogawa, Toshio Ohshiro","doi":"10.5978/islsm.28_19-OR-01","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aims: </strong>Allergic rhinitis annually reach epidemic proportions in Japan. Approximately 30 to 40% of the population suffers from allergic rhinitis during the spring season. Symptoms comprise rhinorrhea, nasal congestion, and sneezing accompanied by irritation and itching of the eyes. The Ohshiro Clinic started using the conventional Nd:YAG laser for the treatment of allergic rhinitis in 1993, and from 2005 we started using a diode laser-pumped Nd:YAG laser. From 2010, we adopted a novel 810 nm diode laser, and the present retrospective study examined the efficacy rate of the treatment of allergic rhinitis in the 2018 season with this system, compared with a previous study in 2011. We aimed to confirm the degree of improvement for each symptom to evaluate effectiveness of the diode laser treatment.</p><p><strong>Subjects and methods: </strong>Between January 8, 2018 and April 30, 2018, a large number of patients consulted our clinic with the major complaint of seasonal allergic rhinitis. They underwent a blood test, and the antigen-specific serum IgE antibody titers were measured for a definitive diagnosis of cedar pollinosis. A total of 211 target patients were treated during the trial period. The average age of the target group was 36.3 years, 134 males, and 77 females. The target patients were treated with lower nasal turbinate mucosal irradiation using a diode laser (ADL-20, Asuka Medical) delivering 810 nm at 7.5 W, with a total energy per treatment of 240 J/cm<sup>2</sup>. We adopted a five-step evaluation in accordance with the Japanese Guidelines for Allergic Rhinitis 2014 for the symptoms of rhinorrhea, sneezing and nasal obstruction. We assessed the degree of improvement in the severity of these symptoms following diode laser treatment from baseline to one month after treatment, in addition to assessing patient satisfaction with the degree of improvement in their quality of life (QOL).</p><p><strong>Results: </strong>The 211 patients positive for cedar pollinosis by the antigen-specific serum IgE antibody tests were broken down by month by number and by improvement, no change or exacerbation as follows. January, 18 patients: 33.4%, 44.4% and 22.2%, respectively. February, 29: 10.4%, 44.4% and 22.2%, respectively. March, 146: 60.3%, 31.5% and 8.2%, respectively. April, 18: 77.8%, 16.7% and 5.5%, respectively. The monthly respective improvement, no change or worse patient QOL as percentages were as follows: January: 16.7%, 44.4% and 38.9%. February: 17.3%, 13.8% and 68.9%. March: 61.6%, 29.5% and 8.9%. April: 94.4%, 0.0% and 5.6%. The values for prevention of exacerbation versus exacerbation for each month were: January, 77.8% vs 22.2%; February, 41.4% vs 58.6%; March, 91.8% vs 8.2%; and April, 94.4% vs 5.6%. The mean efficacy rate for the trial period in the present study was therefore 52.6% which compared very favorably with the mean efficacy rate in the 2011 study of 53.4%.</p><p><strong>Conclusions: </strong>The results showed that the 810 nm diode laser offered a safe and effective solution for the uncomfortable symptoms of allergic rhinitis and could be well applied during the season of Japanese cedar pollen dispersion. Furthermore, a tendency towards high efficacy was demonstrated for laser treatment in class 6 cedar pollinosis patients, based on the specific IgE antibody test.</p>","PeriodicalId":17981,"journal":{"name":"Laser therapy","volume":"28 1","pages":"11-18"},"PeriodicalIF":0.0000,"publicationDate":"2019-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5978/islsm.28_19-OR-01","citationCount":"5","resultStr":"{\"title\":\"Efficacy of seasonal allergic rhinitis using an 810 nm diode laser system.\",\"authors\":\"Katsumi Sasaki, Takafumi Ohshiro, Reiko Sakio, Masahiro Toriumi, Asako Hatano, Emi Fukazawa, Takeyuki Kono, Keisuke Yoshihama, Kaoru Ogawa, Toshio Ohshiro\",\"doi\":\"10.5978/islsm.28_19-OR-01\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and aims: </strong>Allergic rhinitis annually reach epidemic proportions in Japan. Approximately 30 to 40% of the population suffers from allergic rhinitis during the spring season. Symptoms comprise rhinorrhea, nasal congestion, and sneezing accompanied by irritation and itching of the eyes. The Ohshiro Clinic started using the conventional Nd:YAG laser for the treatment of allergic rhinitis in 1993, and from 2005 we started using a diode laser-pumped Nd:YAG laser. From 2010, we adopted a novel 810 nm diode laser, and the present retrospective study examined the efficacy rate of the treatment of allergic rhinitis in the 2018 season with this system, compared with a previous study in 2011. We aimed to confirm the degree of improvement for each symptom to evaluate effectiveness of the diode laser treatment.</p><p><strong>Subjects and methods: </strong>Between January 8, 2018 and April 30, 2018, a large number of patients consulted our clinic with the major complaint of seasonal allergic rhinitis. They underwent a blood test, and the antigen-specific serum IgE antibody titers were measured for a definitive diagnosis of cedar pollinosis. A total of 211 target patients were treated during the trial period. The average age of the target group was 36.3 years, 134 males, and 77 females. The target patients were treated with lower nasal turbinate mucosal irradiation using a diode laser (ADL-20, Asuka Medical) delivering 810 nm at 7.5 W, with a total energy per treatment of 240 J/cm<sup>2</sup>. We adopted a five-step evaluation in accordance with the Japanese Guidelines for Allergic Rhinitis 2014 for the symptoms of rhinorrhea, sneezing and nasal obstruction. We assessed the degree of improvement in the severity of these symptoms following diode laser treatment from baseline to one month after treatment, in addition to assessing patient satisfaction with the degree of improvement in their quality of life (QOL).</p><p><strong>Results: </strong>The 211 patients positive for cedar pollinosis by the antigen-specific serum IgE antibody tests were broken down by month by number and by improvement, no change or exacerbation as follows. January, 18 patients: 33.4%, 44.4% and 22.2%, respectively. February, 29: 10.4%, 44.4% and 22.2%, respectively. March, 146: 60.3%, 31.5% and 8.2%, respectively. April, 18: 77.8%, 16.7% and 5.5%, respectively. The monthly respective improvement, no change or worse patient QOL as percentages were as follows: January: 16.7%, 44.4% and 38.9%. February: 17.3%, 13.8% and 68.9%. March: 61.6%, 29.5% and 8.9%. April: 94.4%, 0.0% and 5.6%. The values for prevention of exacerbation versus exacerbation for each month were: January, 77.8% vs 22.2%; February, 41.4% vs 58.6%; March, 91.8% vs 8.2%; and April, 94.4% vs 5.6%. The mean efficacy rate for the trial period in the present study was therefore 52.6% which compared very favorably with the mean efficacy rate in the 2011 study of 53.4%.</p><p><strong>Conclusions: </strong>The results showed that the 810 nm diode laser offered a safe and effective solution for the uncomfortable symptoms of allergic rhinitis and could be well applied during the season of Japanese cedar pollen dispersion. Furthermore, a tendency towards high efficacy was demonstrated for laser treatment in class 6 cedar pollinosis patients, based on the specific IgE antibody test.</p>\",\"PeriodicalId\":17981,\"journal\":{\"name\":\"Laser therapy\",\"volume\":\"28 1\",\"pages\":\"11-18\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-03-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.5978/islsm.28_19-OR-01\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Laser therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5978/islsm.28_19-OR-01\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Laser therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5978/islsm.28_19-OR-01","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 5
摘要
背景与目的:变应性鼻炎在日本每年达到流行病的程度。大约30%到40%的人在春季患有过敏性鼻炎。症状包括鼻漏、鼻塞和打喷嚏,并伴有眼睛刺激和瘙痒。1993年,Ohshiro诊所开始使用传统的Nd:YAG激光器治疗过敏性鼻炎,从2005年开始,我们开始使用二极管激光泵浦Nd:YAG激光器。从2010年开始,我们采用了一种新型810 nm二极管激光器,本回顾性研究比较了该系统在2018年季节治疗变应性鼻炎的疗效,并与2011年的研究进行了比较。我们的目的是确认每个症状的改善程度,以评估二极管激光治疗的有效性。对象与方法:2018年1月8日至2018年4月30日期间,大量患者以季节性变应性鼻炎为主诉来我院就诊。他们接受了血液测试,并测量了抗原特异性血清IgE抗体滴度,以确定雪松授粉病的诊断。试验期间共治疗211例目标患者。目标人群的平均年龄为36.3岁,男性134人,女性77人。目标患者使用二极管激光器(ADL-20, Asuka Medical)进行下鼻甲粘膜照射,照射功率为810 nm,功率为7.5 W,每次治疗总能量为240 J/cm2。我们根据日本2014年过敏性鼻炎指南对鼻漏、打喷嚏和鼻塞症状采用五步评估。除了评估患者对生活质量(QOL)改善程度的满意度外,我们还评估了从基线到治疗后一个月二极管激光治疗后这些症状严重程度的改善程度。结果:211例雪松花粉病抗原特异性血清IgE抗体检测阳性患者按月、人数、病情改善情况分列如下:1月18例,分别占33.4%、44.4%、22.2%。2月29日:10.4%、44.4%和22.2%。146年3月,分别为60.3%、31.5%和8.2%。4月18日:77.8%,16.7%,5.5%。每月患者生活质量改善、无变化或恶化的百分比分别为:1月:16.7%、44.4%和38.9%。2月份:17.3%、13.8%和68.9%。3月份:61.6%、29.5%和8.9%。4月份:94.4%、0.0%和5.6%。各月预防加重与预防加重的数值分别为:1月,77.8% vs 22.2%;2月,41.4%对58.6%;3月,91.8%对8.2%;4月份为94.4%,4月份为5.6%。因此,本研究试验期间的平均有效率为52.6%,与2011年研究的平均有效率53.4%相比非常有利。结论:810 nm二极管激光治疗变应性鼻炎是一种安全有效的治疗方法,可应用于杉木花粉弥散季节。此外,基于特异性IgE抗体测试,激光治疗6类雪松花粉症患者的疗效趋于高。
Efficacy of seasonal allergic rhinitis using an 810 nm diode laser system.
Background and aims: Allergic rhinitis annually reach epidemic proportions in Japan. Approximately 30 to 40% of the population suffers from allergic rhinitis during the spring season. Symptoms comprise rhinorrhea, nasal congestion, and sneezing accompanied by irritation and itching of the eyes. The Ohshiro Clinic started using the conventional Nd:YAG laser for the treatment of allergic rhinitis in 1993, and from 2005 we started using a diode laser-pumped Nd:YAG laser. From 2010, we adopted a novel 810 nm diode laser, and the present retrospective study examined the efficacy rate of the treatment of allergic rhinitis in the 2018 season with this system, compared with a previous study in 2011. We aimed to confirm the degree of improvement for each symptom to evaluate effectiveness of the diode laser treatment.
Subjects and methods: Between January 8, 2018 and April 30, 2018, a large number of patients consulted our clinic with the major complaint of seasonal allergic rhinitis. They underwent a blood test, and the antigen-specific serum IgE antibody titers were measured for a definitive diagnosis of cedar pollinosis. A total of 211 target patients were treated during the trial period. The average age of the target group was 36.3 years, 134 males, and 77 females. The target patients were treated with lower nasal turbinate mucosal irradiation using a diode laser (ADL-20, Asuka Medical) delivering 810 nm at 7.5 W, with a total energy per treatment of 240 J/cm2. We adopted a five-step evaluation in accordance with the Japanese Guidelines for Allergic Rhinitis 2014 for the symptoms of rhinorrhea, sneezing and nasal obstruction. We assessed the degree of improvement in the severity of these symptoms following diode laser treatment from baseline to one month after treatment, in addition to assessing patient satisfaction with the degree of improvement in their quality of life (QOL).
Results: The 211 patients positive for cedar pollinosis by the antigen-specific serum IgE antibody tests were broken down by month by number and by improvement, no change or exacerbation as follows. January, 18 patients: 33.4%, 44.4% and 22.2%, respectively. February, 29: 10.4%, 44.4% and 22.2%, respectively. March, 146: 60.3%, 31.5% and 8.2%, respectively. April, 18: 77.8%, 16.7% and 5.5%, respectively. The monthly respective improvement, no change or worse patient QOL as percentages were as follows: January: 16.7%, 44.4% and 38.9%. February: 17.3%, 13.8% and 68.9%. March: 61.6%, 29.5% and 8.9%. April: 94.4%, 0.0% and 5.6%. The values for prevention of exacerbation versus exacerbation for each month were: January, 77.8% vs 22.2%; February, 41.4% vs 58.6%; March, 91.8% vs 8.2%; and April, 94.4% vs 5.6%. The mean efficacy rate for the trial period in the present study was therefore 52.6% which compared very favorably with the mean efficacy rate in the 2011 study of 53.4%.
Conclusions: The results showed that the 810 nm diode laser offered a safe and effective solution for the uncomfortable symptoms of allergic rhinitis and could be well applied during the season of Japanese cedar pollen dispersion. Furthermore, a tendency towards high efficacy was demonstrated for laser treatment in class 6 cedar pollinosis patients, based on the specific IgE antibody test.